Search results
Results From The WOW.Com Content Network
Giant cell arteritis typically only occurs in those over the age of 50; [4] particularly those in their 70s. [22] It affects about 1 in 15,000 people over the age of 50 per year. [ 2 ] It is more common in women than in men, by a ratio of 2:1, [ 4 ] and more common in those of Northern European descent, as well as in those residing further from ...
Arteritic anterior ischemic optic neuropathy (arteritic AION, A-AION or AAION) is vision loss that occurs in giant cell arteritis (also known as temporal arteritis). Temporal arteritis is an inflammatory disease of medium-sized blood vessels that happens especially with advancing age.
The halo sign of temporal arteritis should not be confused with Deuel's halo sign, which is a sign of fetal death. [ 3 ] The halo sign is also understood as a region of ground-glass attenuation surrounding a pulmonary nodule on an X-ray computed tomography (CT scan) of the chest.
Arteritis is a vascular disorder characterized by inflammation of the walls of arteries, [1] usually as a result of infection or autoimmune responses. Arteritis, a complex disorder, is still not entirely understood. [2] Arteritis may be distinguished by its different types, based on the organ systems affected by the disease. [2]
The 2012 Chapel Hill Consensus Conference defines large vessel vasculitis (LVV) as a type of vasculitis that can affect any size artery, but it usually affects the aorta and its major branches more frequently than other vasculitides. [4] Takayasu arteritis (TA) and giant cell arteritis (GCA) are the two main forms of LVV. [5]
A giant cell (also known as a multinucleated giant cell, or multinucleate giant cell) is a mass formed by the union of several distinct cells (usually histiocytes), often forming a granuloma. [ 1 ] Although there is typically a focus on the pathological aspects of multinucleate giant cells (MGCs), they also play many important physiological roles.
The ACR White Paper on MR Safety has been rewritten and was released early in 2007 under the new title ACR Guidance Document for Safe MR Practices. In December 2007, the Medicines and Healthcare products Regulatory Agency (MHRA), a UK healthcare regulatory body, issued their Safety Guidelines for Magnetic Resonance Imaging Equipment in Clinical ...
The full clinical picture was first presented by Friedrich Wegener (1907–1990), a German pathologist, in two reports in 1936 and 1939, leading to the eponymous name Wegener's granulomatosis or Wegener granulomatosis (English: / ˈ v ɛ ɡ ə n ər /). [10]